Continuous Bioprocessing Platforms

Just - Evotec Biologics has developed and  proven an integrated continuous biomanufacturing platform. It combines a perfusion cell culture step with a fully connected and intensified downstream process. We manufacture drug substance using hybrid (‘semi-continuous’) or fully continuous (‘end-to-end’) modes of operation using either 500L or 1000L scale single-use bioreactors depending on the amount of drug substance needed.

Our continuous bioprocess platform is designed to produce monoclonal antibody, bispecific antibody, biosimilars and next-generation biologics.

1 1 1 3 2 J JEB focus areaa

Continuous Biomanufacturing Maximizes Flexibility

Our continuous manufacturing approach is extremely flexible while capable of delivering the high mass outputs more commonly associated with traditional large-scale stainless-steel fed-batch facilities. We have high expressing cell lines and integrated single-use upstream and downstream processing unit operations to maximize process intensification. Our innovative control strategy is enabled by our proprietary automation.

Continuous Processing Platofrms Used At Just Evotec Biologics

Process Development for Continuous Bioproduction

Just – Evotec Biologics scientists are experienced in process development for continuous biomanufacturing. We perform process development for biopharmaceuticals in pre- and early-phase clinical development. Our expertise extends to converting existing fed-batch processes to our continuous biomanufacturing platform in preparation for commercial launch.

Highest Biologics Product Quality

Within our continuous bioprocess platform, an intensified perfusion cell culture process results in high and consistent viable cell densities. Our process controls and process analytical technologies ensure the cell culture is held in a ‘steady state’ resulting in greater product consistency.

Perfusion cell culture allows cells to be maintained in a healthier state than in fed-batch manufacturing and reduces the leakage of intracellular contents, such as proteases, that degrade biological products. In this way, perfusion cell cultures are capable of delivering the highest biopharmaceutical product quality.

Maximum Bioprocess Productivity

Drug substance manufacturing throughput is ramped up to meet product demand simply by extending the perfusion time and increasing the number of downstream cycles. We have proven that we can significantly increase productivity compared to traditional fed batch processes.

Lowest Biopharmaceutical COGs

Our fully end-to-end continuous bioprocessing strategy can deliver titers of 4 g/L/day or more and can reduce COGs for a monoclonal antibody by as much as 75% for a commercial product1

We are committed to achieving COGs below US$ 50 per gram, as part of our mission to dramatically expand access to biotherapeutics.

1) Garcia F.A & Gefroh E., Drug Discovery Today (2023)

1 1 1 3 2 K JEB focus areaa
Philip Boehme

Philip Boehme

EVP Partnering & Transformation

vCard
Logo Just white
Just – Evotec Biologics is a mission-driven Business Unit of Evotec with the aim of radically improving access to biologics through a de-risked, agile approach, coupled with significantly lower manufacturing cost. Over the years we have advanced an industry-transforming bioprocessing platform, which we leverage with our partners to drive what we call the paradigm shift in biologics.